DE69630033D1 - Immunologische kombinationsmittel und dazugehörige verfahren - Google Patents

Immunologische kombinationsmittel und dazugehörige verfahren

Info

Publication number
DE69630033D1
DE69630033D1 DE69630033T DE69630033T DE69630033D1 DE 69630033 D1 DE69630033 D1 DE 69630033D1 DE 69630033 T DE69630033 T DE 69630033T DE 69630033 T DE69630033 T DE 69630033T DE 69630033 D1 DE69630033 D1 DE 69630033D1
Authority
DE
Germany
Prior art keywords
lipoprotein
antigen
related methods
compositions
combination agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69630033T
Other languages
English (en)
Other versions
DE69630033T2 (de
Inventor
S Becker
C Huebner
B Gray
S Biscardi
F Erdile
Bruno Guy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Aventis Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur Inc filed Critical Aventis Pasteur Inc
Publication of DE69630033D1 publication Critical patent/DE69630033D1/de
Application granted granted Critical
Publication of DE69630033T2 publication Critical patent/DE69630033T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/828—Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69630033T 1995-06-07 1996-06-05 Immunologische kombinationsmittel und dazugehörige verfahren Expired - Fee Related DE69630033T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US476656 1995-06-07
US08/476,656 US6251405B1 (en) 1995-06-07 1995-06-07 Immunological combination compositions and methods
US588621 1996-01-19
US08/588,621 US6379675B1 (en) 1995-06-07 1996-01-19 Immunological combination compositions and methods
PCT/US1996/008866 WO1996040290A1 (en) 1995-06-07 1996-06-05 Immunological combination compositions and methods

Publications (2)

Publication Number Publication Date
DE69630033D1 true DE69630033D1 (de) 2003-10-23
DE69630033T2 DE69630033T2 (de) 2004-04-01

Family

ID=23892726

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69630033T Expired - Fee Related DE69630033T2 (de) 1995-06-07 1996-06-05 Immunologische kombinationsmittel und dazugehörige verfahren

Country Status (12)

Country Link
US (5) US6251405B1 (de)
EP (1) EP0831937B1 (de)
JP (1) JPH11510370A (de)
AT (1) ATE249844T1 (de)
AU (1) AU717890B2 (de)
CA (1) CA2223041A1 (de)
DE (1) DE69630033T2 (de)
FI (1) FI118591B (de)
IL (1) IL118579A (de)
NO (1) NO975620L (de)
WO (1) WO1996040290A1 (de)
ZA (1) ZA964894B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
CA2289966A1 (en) * 1997-05-14 1998-11-19 Galen (Chemicals) Limited Topical compositions
CA2304128A1 (en) * 1997-09-18 1999-03-25 Robert Becker Improved method of production of pneumococcal surface proteins
WO2000000218A1 (fr) * 1998-06-26 2000-01-06 Aventis Pasteur Immunisation a ciblage mucosal
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
WO2000062800A2 (en) 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
EP1683867B1 (de) 1999-06-18 2014-04-09 Research Foundation Of State University Of New York Gruppen von Borrelia burgdorferi und Borrelia afzelii, die Lyme Krankheit in Menschen verursachen
EP1235588A2 (de) * 1999-12-09 2002-09-04 Institut Pasteur Durch mukosale verabreichung ohne adjuvans von polypeptiden mit lipidische ende induzierte systemische immunantwort
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
CA2418036A1 (en) * 2000-07-31 2002-02-07 Yale University Innate immune system-directed vaccines
DE60131982T2 (de) 2000-08-18 2008-12-11 Brookhaven Science Associates Llc Veränderte borrelia burgdorferi ospa
EP1939294A1 (de) 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Rekombinante Konstrukte von Borrelia Burgdorferi
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
JP5033303B2 (ja) 2001-07-05 2012-09-26 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
US7923023B2 (en) * 2002-02-25 2011-04-12 Astech International LLC Method and composition for delivery of medicants to animals
US20080299140A1 (en) * 2002-05-24 2008-12-04 The Regents Of The University Of California, Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition
FR2846004B1 (fr) * 2002-10-16 2006-06-23 Maco Pharma Sa Composition pour culture de cellules notamment animales ou de tissus, comprenant du polyethylene glycol
US7795223B2 (en) * 2004-05-27 2010-09-14 Novozymes Biopharma Au Ltd. Treatment of inflammatory airway disease
US8029777B2 (en) 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
CA2576280A1 (en) 2004-08-13 2006-02-16 Barry J. Marshall Helicobacter pylori-based delivery system
EP1991264B1 (de) 2006-03-07 2015-01-07 Vaxinnate Corporation Zusammensetzungen mit hämagglutinin, verfahren zu ihrer herstellung und verfahren zu ihrer verwendung
US8426163B2 (en) * 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
WO2009131665A1 (en) 2008-04-22 2009-10-29 Research Foundation Of State University Of New York Borrelia burgdorferi cell envelope protein array
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
WO2010148496A1 (en) * 2009-06-22 2010-12-29 National Health Research Institutes Lipidated tumor- associated antigens and immunotherapeutic compositions
EP2475385A1 (de) * 2009-09-10 2012-07-18 Novartis AG Kombinationsimpfstoffe gegen atemwegserkrankungen
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
KR101948670B1 (ko) 2010-12-29 2019-02-15 오션스파 인코퍼레이티드 중앙 스파 피쉬 펜
RU2737638C2 (ru) * 2013-12-03 2020-12-01 Вирометикс Аг ПРОЛИН-БОГАТЫЕ ПЕПТИДЫ, ЗАЩИЩАЮЩИЕ ОТ S.pneumoniae
JP2017531657A (ja) 2014-10-07 2017-10-26 ザ リサーチ ファンデーション フォー ザ ステート ユニバーシティ オブ ニューヨーク 組換えボレリアタンパク質およびその使用のための方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4302386A (en) * 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US4455142A (en) 1980-07-07 1984-06-19 Alza Corporation Method of coadministering an antigen and an immunopotentiator
US4484923A (en) * 1982-03-25 1984-11-27 Alza Corporation Method for administering immunopotentiator
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US4839293A (en) * 1986-02-24 1989-06-13 The Trustees Of Columbia University In The City Of New York DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof
US4721617A (en) 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
EP0270295A3 (de) * 1986-12-03 1989-08-02 Connaught Laboratories Limited Konjugat-Impfstoff
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5098997A (en) * 1987-12-11 1992-03-24 Praxis Biologics, Inc. Vaccines for Haemophilus influenzae
WO1990003441A1 (en) 1988-09-20 1990-04-05 Marvin Murray Accelerated microdilution determination of bacteria susceptibility to antibiotics
DK0506868T4 (da) 1989-12-22 2004-04-26 Mikrogen Molekularbiol Entw Immunologisk aktive proteiner fra Borrelia burgdorferi, tilhørende testkits og vaccine
CA2032914A1 (en) * 1989-12-26 1991-06-27 Peter C.K. Lau Use of bacterial lipoprotein amino terminus in fusion plasmids for in vivo expression of lipid modified polypeptides
ZA921025B (en) 1991-02-15 1992-11-25 Uab Research Foundation Structural gene of pneumococcal protein
WO1993004175A1 (en) * 1991-08-15 1993-03-04 Smithkline Beecham Biologicals (S.A.) Osp a proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
WO1993007897A1 (en) * 1991-10-21 1993-04-29 Medimmune, Inc. Bacterial expression vectors containing dna encoding secretion signals of lipoproteins
EP0540457A1 (de) * 1991-10-22 1993-05-05 Symbicom Ab Verbesserungen der Diagnose und der Prophylaxe von Borrelia burgdorferi
CA2105629A1 (en) * 1992-09-14 1994-03-15 Robert S. Becker Potentiation of immunogenic response
WO1994014318A1 (en) * 1992-12-24 1994-07-07 Medimmune, Inc. Method of protection against streptococcus pneumoniae with transformed mycobacteria
FR2708622B1 (fr) * 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.

Also Published As

Publication number Publication date
FI974423A (fi) 1998-02-04
CA2223041A1 (en) 1996-12-19
EP0831937B1 (de) 2003-09-17
FI118591B (fi) 2008-01-15
JPH11510370A (ja) 1999-09-14
WO1996040290A1 (en) 1996-12-19
EP0831937A1 (de) 1998-04-01
AU717890B2 (en) 2000-04-06
EP0831937A4 (de) 2001-09-19
NO975620D0 (no) 1997-12-04
IL118579A (en) 2007-12-03
AU6151996A (en) 1996-12-30
US6984385B2 (en) 2006-01-10
US20080089911A1 (en) 2008-04-17
US20060110408A1 (en) 2006-05-25
FI974423A0 (fi) 1997-12-05
IL118579A0 (en) 1996-10-16
ATE249844T1 (de) 2003-10-15
US20020131983A1 (en) 2002-09-19
NO975620L (no) 1998-02-04
DE69630033T2 (de) 2004-04-01
US7235243B2 (en) 2007-06-26
ZA964894B (en) 1997-02-24
US6379675B1 (en) 2002-04-30
US6251405B1 (en) 2001-06-26

Similar Documents

Publication Publication Date Title
DE69630033D1 (de) Immunologische kombinationsmittel und dazugehörige verfahren
UA49814C2 (uk) Композиція, яка містить антиген вірусу папіломи, спосіб лікування цервікального раку, спосіб лікування гострокінцевої кондиломи
FI972945A (fi) Antigeenien antamiseen soveltuvia koostumuksia
ATE284710T1 (de) Adjuvans für vitale impfstoffe
BR9107206A (pt) Processo para produzir uma variante de proteina que evoca uma resposta imunogenica diminuida em animais,produtos obtidos,composicao e uso
NO912630D0 (no) Fremgangsmaate for fremstilling av nye 2,6-dialkyl-4-silyl-fenoler.
NL300363I1 (nl) Vaccin omvattende olie/water-emulsie met tocoferolen squaleen
PT745388E (pt) Composicao de vacinas para mamiferos compreendendo esqualeno ou esqualano fosfolipido e um tensioactivo como adjevante
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
HUP0101323A1 (hu) Vakcinakészítmények
FR2686896B1 (fr) Mutant attenue de listeria monocytogenes; souche recombinante de listeria monocytogenes, utilisation comme vecteurs heterologues d'antigenes vaccinal et utilisation comme vaccin ou composition diagnostique.
PT789590E (pt) Imunopotenciacao induzida por quitosano
ATE201880T1 (de) Oberflächenaktive zusammensetzungen und verfahren
FI972054A0 (fi) Immunogeenisiä koostumuksia
HK1085646A1 (en) Antigenic compositions for immunization of non-human mammals against streptococcus equi
DE69828043D1 (de) Fluoridfreie zahnremineralisierung
YU48525B (sh) Protein, dnk koji kodira protein, rekombinantni vektor koji obuhvata dnk i postupak za proizovodnju proteina
ES2058764T3 (es) Composiciones orales.
ATE204093T1 (de) Drahtlackformulierung mit internem gleitmittel
AU4537100A (en) Adjuvant combinations for immunization composition and vaccines
DK0721782T3 (da) Influenzavaccine indeholdende pertussistoksin
CA2026493A1 (fr) Alkylcarbamates de triglycerol, leur preparation et leur application notamment comme agents emulsionnants dans des compositions cosmetiques sous forme de microdispersions de cires

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee